844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      2017 News

      Keyword Search
       
      2017 | 2016 | 2015 | 2014
      DateTitle 
      04/04/17NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
      by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA   April 4, 2017 -  NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Joining NantKwest as a new investor in Viracta is Wicklow Capital. Viracta's founding investors, Latterell Venture... 
      Printer Friendly Version
      03/20/17NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced today that the FDA has granted Orphan Drug Designation to the company’s activated natural killer (aNK) cell therapy for treatment of patients... 
      Printer Friendly Version
      03/06/17NantKwest to Present at Upcoming Investor Conferences
      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference on Wednesday, March 8th, at 9:20am ET in Boston, MA 29th Annual Roth Conference on Monday, March 13th, at 12:00pm ET in Dana Point, CA ... 
      Printer Friendly Version
      01/23/17Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
      CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized the company's Investigational New Drug Application (IND) for its ... 
      Printer Friendly Version